Loading...
Loading...
EQ| Name | Value |
|---|---|
| Revenues | 15.8M |
| Cost of Revenue | 0.0M |
| Gross Profit | 15.8M |
| Operating Expense | 13.7M |
| Operating I/L | 2.0M |
| Other Income/Expense | 0.7M |
| Interest Income | 0.2M |
| Pretax | 2.8M |
| Income Tax Expense | -1.0M |
| Net Income/Loss | 3.8M |
Equillium, Inc. is a clinical-stage biotechnology company specializing in the development and sale of products for severe autoimmune and immuno-inflammatory disorders. Its lead product candidate, itolizumab (EQ001), is a monoclonal antibody targeting the immune checkpoint receptor CD6. It is currently in Phase III clinical trials for acute graft-versus-host disease and has completed Phase Ib trials for asthma and lupus nephritis. The company also develops EQ101 for cutaneous T cell lymphoma and alopecia areata, and EQ102 for various gastrointestinal diseases.
